Biggest News Aggregation in the World
๐Ÿ“ฐ Multiple Sclerosis Centers News

Page 3 - Multiple Sclerosis Centers News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Multiple Sclerosis Centers. Real-time updates on events, politics, business and more.

TG Therapeutics Announces Data from the ULTIMATE I and II Phase 3 Trials of BRIUMVI in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK - TG Therapeutics, Inc. , today announced the details of an upcoming oral presentation, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI in patients with... | June 1, 2023
United States Lawrence Steinman Enrique Alvarez Consortium Of Multiple Sclerosis Centers International Journal Biopharmaceutical Company

Sanofi - Aventis Groupe: Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis

Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis Frexalimab met primary
France General Sally Bain Eva Schaefer Jansen Tarik Elgoutni Erik Wallstr Corentine Driancourt

TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

31.05.2023 - NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) - TG Therapeutics, Inc.ย (NASDAQ: TGTX),ย today announced the details of an upcoming oral presentation, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI (ublituximab-xiiy) in ... Seite 1
United States International Journal Globe Newswire Tg Therapeutics Inc Consortium Of Multiple Sclerosis Centers Multiple Sclerosis Centers Ublituximab Is Associated

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Sanofi MS Drug Shines in Phase 2, Paving Way for a Pivotal Test Next Year

Frexalimab, a Sanofi drug candidate with roots at Dartmouthโ€™s medical school, has met the main goal of its Phase 2 test. The encouraging data for this program come as different experimental Sanofi MS drug nears its one-year anniversary under FDA clinical hold.
United States Principia Biopharma Erik Wallstr Geisel School Of Medicine At Dartmouth Consortium Of Multiple Sclerosis Centers Multiple Sclerosis Centers

EQS-News: Immunic to Participate in Scientific and Investor Conferences in June

Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific and Investor Conferences in June 30.05.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Scientific and Investor Conferences in June NEW YORK,...
United States Aurora Hall Edna Kaplan Paula Schwartz Robertj Fox Jessica Breu

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science